hGLP1R(SD) Rat
Product Name
hGLP1R(SD) Rat
Product ID
CR014
Strain Name
SD-Glp1rem1(hGLP1R)/Cya
Background
SD
Status
When using this mouse strain in a publication, please cite “hGLP1R(SD) Rat (Catalog CR014) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
Gene Name
GLP1R
Gene Alias
GLP-1, GLP-1R, GLP-1-R
NCBI ID
Chromosome
Chr 6 (Human)
MGI ID
Datasheet
Strain Description
The glucagon-like peptide-1 receptor (GLP-1R), encoded by the GLP1R gene, is the receptor for endogenous glucagon-like peptide-1 (GLP-1) and belongs to the class B (secretin-like) G protein-coupled receptor (GPCR) family. GLP-1R contains a characteristic seven-transmembrane domain (7TM) and a relatively large N-terminal extracellular domain, and mediates downstream signaling upon binding to GLP-1 [1]. GLP-1R is predominantly expressed in pancreatic β cells and is also detected in the central nervous system and other tissues. Upon ligand activation, GLP-1R can undergo internalization and participate in the regulation of insulin secretion and energy metabolism [2-3]. Activation of GLP-1R enhances glucose-dependent insulin secretion and inhibits glucagon secretion, while also delaying gastric emptying and reducing food intake [3-4]. GLP-1 receptor agonists (GLP-1RAs) are important therapeutic agents for the treatment of type 2 diabetes (T2D) and obesity, and improve glycemic control and promote weight loss through these multiple mechanisms [4]. In addition, GLP-1R-related signaling has been extensively investigated for its potential neuroprotective effects. Neuroprotective effects of GLP-1R agonists have been observed in animal models of stroke, although their clinical value for the direct treatment of acute stroke requires further investigation [5].
The hGLP1R(SD) Rat was generated by gene editing to replace a partial coding sequence of exon 1 and a partial sequence of intron 1 of the rat Glp1r gene with "Exon 1~2 of Human GLP1R CDS (without signal peptide)-Human GLP1R intron 2-Exon 3~13 of Human GLP1R CDS-hGH pA", while retaining the genomic sequence encoding the signal peptide of rat GLP1R. Its potential applications mainly include mechanistic studies of type 2 diabetes (T2D), obesity, and other metabolic diseases, as well as pharmacological studies of GLP-1R-targeted therapeutics, candidate drug screening, and evaluation of their potential effects.
Reference
Yang D, de Graaf C, Yang L, et al. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R). J Biol Chem. 2016;291(25):12991-13004.
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H., & Barkas, F. (2026). GLP-1 Receptor Agonists in Acute Ischemic Stroke and Secondary Stroke Prevention: A Narrative Review of Preclinical and Clinical Evidence. Journal of central nervous system disease, 18, 11795735261444425.
Drucker D. J. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular metabolism, 57, 101351. https://doi.org/10.1016/j.molmet.2021.101351
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular metabolism, 46, 101102.
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021). Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 41(1), 14–30.
Strain Strategy
The partial coding sequence of exon 1 and partial intron 1 of the rat Glp1r gene were replaced with the cassette "Exon 1~2 of Human GLP1R CDS (without signal peptide)-Human GLP1R intron 2-Exon 3~13 of Human GLP1R CDS-hGH pA", while the sequence encoding the signal peptide of the rat GLP1R protein was retained.
Figure 1. Gene editing strategy for hGLP1R(SD) rats.
Application Area
Mechanism studies of type 2 diabetes (T2D), obesity, and other metabolic diseases;
Pharmacological studies of GLP-1R targeted drugs, candidate drug screening, and potential efficacy evaluation.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.